AU637903B2 - Phosphonopeptides with collagenase inhibiting activity - Google Patents
Phosphonopeptides with collagenase inhibiting activity Download PDFInfo
- Publication number
- AU637903B2 AU637903B2 AU76502/91A AU7650291A AU637903B2 AU 637903 B2 AU637903 B2 AU 637903B2 AU 76502/91 A AU76502/91 A AU 76502/91A AU 7650291 A AU7650291 A AU 7650291A AU 637903 B2 AU637903 B2 AU 637903B2
- Authority
- AU
- Australia
- Prior art keywords
- formula
- amino
- diazacyclotridecan
- hydrogen
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108060005980 Collagenase Proteins 0.000 title description 19
- 102000029816 Collagenase Human genes 0.000 title description 19
- 229960002424 collagenase Drugs 0.000 title description 8
- 230000002401 inhibitory effect Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 163
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 31
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 25
- -1 t- butoxycarbonyl Chemical group 0.000 claims description 25
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 15
- 150000002431 hydrogen Chemical group 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- 210000002808 connective tissue Anatomy 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 230000015556 catabolic process Effects 0.000 claims description 8
- 238000006731 degradation reaction Methods 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 150000004677 hydrates Chemical class 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 125000003435 aroyl group Chemical group 0.000 claims description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 claims 6
- PRUDYSQUBNAOJO-UHFFFAOYSA-N 7-amino-1,7-diazacyclotridecan-8-one Chemical compound NN1CCCCCNCCCCCC1=O PRUDYSQUBNAOJO-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 101100063818 Caenorhabditis elegans lig-1 gene Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241000406799 Deto Species 0.000 claims 1
- 101100257062 Leishmania major IPCS gene Proteins 0.000 claims 1
- 101100224228 Mus musculus Lig1 gene Proteins 0.000 claims 1
- 101000881330 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Dynein heavy chain, cytoplasmic Proteins 0.000 claims 1
- 108090001109 Thermolysin Proteins 0.000 claims 1
- 235000005505 Ziziphus oenoplia Nutrition 0.000 claims 1
- 244000104547 Ziziphus oenoplia Species 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 117
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 94
- 239000000203 mixture Substances 0.000 description 53
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 49
- 239000000243 solution Substances 0.000 description 46
- 239000003921 oil Substances 0.000 description 38
- 235000019198 oils Nutrition 0.000 description 38
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
- 238000000746 purification Methods 0.000 description 24
- 238000003756 stirring Methods 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 238000003818 flash chromatography Methods 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 150000005690 diesters Chemical class 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- 235000019341 magnesium sulphate Nutrition 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 150000003951 lactams Chemical class 0.000 description 12
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 11
- 150000001299 aldehydes Chemical class 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical group 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 238000005984 hydrogenation reaction Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000002917 arthritic effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 238000007429 general method Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 102000005741 Metalloproteases Human genes 0.000 description 5
- 108010006035 Metalloproteases Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000006386 Myelin Proteins Human genes 0.000 description 4
- 108010083674 Myelin Proteins Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000010936 aqueous wash Methods 0.000 description 4
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 4
- 239000002442 collagenase inhibitor Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 210000005012 myelin Anatomy 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000006268 reductive amination reaction Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 208000016192 Demyelinating disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108091006629 SLC13A2 Proteins 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003366 colagenolytic effect Effects 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 229910000510 noble metal Inorganic materials 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NAMHUDHCBIJIMK-UHFFFAOYSA-N 1,3-diazacyclotridecan-2-one Chemical compound O=C1NCCCCCCCCCCN1 NAMHUDHCBIJIMK-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 102220347504 c.86A>C Human genes 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- RQKYHDHLEMEVDR-UHFFFAOYSA-N oxo-bis(phenylmethoxy)phosphanium Chemical compound C=1C=CC=CC=1CO[P+](=O)OCC1=CC=CC=C1 RQKYHDHLEMEVDR-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 2
- 150000003017 phosphorus Chemical class 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108010054626 proteoglycan-degrading metalloendopeptidases Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229940080313 sodium starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 125000004665 trialkylsilyl group Chemical group 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical group FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- GJFNRSDCSTVPCJ-UHFFFAOYSA-N 1,8-bis(dimethylamino)naphthalene Chemical compound C1=CC(N(C)C)=C2C(N(C)C)=CC=CC2=C1 GJFNRSDCSTVPCJ-UHFFFAOYSA-N 0.000 description 1
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- SFJQXSBIWRZKFL-UHFFFAOYSA-N 1-bis(phenylmethoxy)phosphorylpropan-1-ol Chemical compound C=1C=CC=CC=1COP(=O)(C(O)CC)OCC1=CC=CC=C1 SFJQXSBIWRZKFL-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008642 Cholesteatoma Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 229940122097 Collagenase inhibitor Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 1
- 101000741967 Homo sapiens Presequence protease, mitochondrial Proteins 0.000 description 1
- 101001116987 Homo sapiens Proton-coupled folate transporter Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 229920006063 Lamide® Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- JOOMLFKONHCLCJ-UHFFFAOYSA-N N-(trimethylsilyl)diethylamine Chemical compound CCN(CC)[Si](C)(C)C JOOMLFKONHCLCJ-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 102100038632 Presequence protease, mitochondrial Human genes 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102100024267 Proton-coupled folate transporter Human genes 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-RNFDNDRNSA-N Sulfur-36 Chemical compound [36S] NINIDFKCEFEMDL-RNFDNDRNSA-N 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- CZHYKKAKFWLGJO-UHFFFAOYSA-N dimethyl phosphite Chemical compound COP([O-])OC CZHYKKAKFWLGJO-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229940042400 direct acting antivirals phosphonic acid derivative Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- QVDYYQXUNAQSNI-UHFFFAOYSA-N ethyl acetate;pentane Chemical compound CCCCC.CCOC(C)=O QVDYYQXUNAQSNI-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- DODCBMODXGJOKD-RGMNGODLSA-N methyl (2s)-2-amino-4-methylpentanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC(C)C DODCBMODXGJOKD-RGMNGODLSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003138 primary alcohols Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 102220223285 rs1060502353 Human genes 0.000 description 1
- 102220098272 rs878853037 Human genes 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
OPI DATE 30/10/91 APPLN. ID 76502 91 AOJP DATE 05/12/91
PCT
PCT NUMBER PCT/GB91/00529 INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 5 (11) International Publication Number: WO 91/15506 C07K 5/06, A61K 37/64 Al (43) International Publication Date: 17 October 1991 (17.10.91) (21) International Application Number: PCT/GB91/00529 (74)Agents: RUSSELL, Brian, John et al.; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bot- (22) International Filing Date: 5 April 1991 (05.04.91) tom Road, Epsom, Surrey KT18 5XQ (GB).
Priority data: (81) Designated States: AT (European patent), AU, BE (Euro- 9008065.6 10 April 1990 (10.04.90) GB pean patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (71) Applicant (for all designated States except US): BEECHAM (European patent), IT (European patent), JP, KR, LU GROUP P.L.C. [GB/GB]; SB House, Great West Rcad, (European patent), NL (European patent), SE (Euro- Br,ntford, Middl.esex T8. 9DD pean patent), US.
Fowr" A'e.w l4ik^s A Ca$t Nel flOLX4tll.n/" (72) Inventors; and re ./tj d /Add4/e.s e TW bPi s /d k'a 1t Inventors/Applicants (for US only) MARKWELL, Roger, Published Edward [GB/GB]; RAHMAN, Shahzad, Sharooq [BD/ Wi;h international search report.
GB]; WARD, Robert, William [GB/GB]; SmithKline Before the expiration of the time limit for amending the Beecham Pharmaceuticals, Coldharbour Road, The Pin- claims and to be republished in the event of the receipt of nacles, Harlow, Essex CM19 SAD amendments.
'i lo (54) Title: PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY R R 2 1 2 o
O
1 R 4 0-P N N (I) OR H H OR 0 R3 (57) Abstract Azalactam derivatives processes for their preparation and their use as collagenase inhibitors having structure WO 9115506PCT/GB9 1/00529 PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY The poresent invention relates to novel phosphorus derivatives, processes for their preparation and their use in medicine. In particular, the present invention relates to their use as inhibitors of enzymes of the collagenase family of neutr~l metalloproteases, for treating arthritic and other diseases.
The mammalian collagenase family of enzymes comprises a number of proteases, exemplified by interstitial (type t collagenase itself, the stromelysins (also known as proteoglycanases or transins), fibroblast and polymorphonuclear l~~eucocyte gelatinases (also known as collagen-IV-ases), and 'pump-i' (putative metalloprotease 1, uterine metalloprotease). Membership of the mammalian collagenase family of proteases is evident by possession of a number of b~ighly characteristic and experimcntally verifiable properties. [Goldberg et al., J. Biol. Chem.
2610, 6600, 1986; Whitham et al., Biochem. 3. 240, 913, 1986; Breathnach et al., Nucleic Acids Res., 139, 1987; Muller et al., Biochem. 253, 187, 1986; Collie= etal., 3. Biol. Chem., 263, 6579, 1988; Murphy et al., Biochem. 258, 463, 1989; Quantin et al., Biochem.
28, 5327, 1989; Birkedal-Hansen, 3. Oral Pathol., 7,445, 1988).
The range of therapeutic applications of the inventic;:.
described hereinafter reflects the fundamental role ,F collagen and other proteinaceous substrates of th~e czllagenase family of e-nzvme.s in the connective tissue matrix throughouat the body. Appli1cations extend to clin-ical interventions in many diseases and Phenomena invol-ving the destruction of collagen and other conneczive tissue components, and also normal or di1-soraerec tissue remodelling.
WO 91/15506 PCIT/GB91/00529 -2- Inhibitors of the collagenase family of enzymes are considered to provide useful treatments for: arthritic diseases, such as rheumatoid and osteoarthritis, soft tissue rheumatism, polychondritis and tendonitis; bone resorption diseases, such as osteoporosis, Paget's disease, hyperparathyroidism and cholesteatoma; the enhanced collagen destruction that occurs in association with diabetes; the recessive classes of dystrophic epidermolysis bullosa; periodontal disease and related consequences of gingival production of collagenase, or of PMNL collagenase release following cellular infiltration to inflamed gingiva, including by combating the greater susceptibility of diabetes patients to periodontal disease; corneal ulceration, e.g. that induced by alkali or other burns, by radiation, by vitamin E or retinoid deficiency; ulceration of the skin and gastro-intestinal tract, and abnormal wound healing; postoperative conditions, including colonic anastomosis, in which collagenase levels are raised; cancer, where members of the collagenase family of enzymes have been implicated in the neovascularization required to support tumour growth and survival Basset et al. Nature, 348, 699, 1990] in the tissue remodelling required to accommodate the growing primary and secondary tumours, and in the penetration of tumour cells through the basement membrane of the vascular walls during metastasis; and demyelinating diseases of the central and peripheral nervous systems, including syndromes in which myelin loss is the primary pathological event and those in which demyelination follows axonal atrophy. The degradation of myelin in these diseases, exemplified by multiple sclerosis, is mediated by members of the collagenase family of enzymes.
WO 91/15506 PCT/GB91/00529 3 As a particular example of'the therapeutic value of inhibitors of the collagenase family of enzymes such as are disclosed in the present invention, chronic arthritic diseases leading to extensive loss of the collagen, proteoglycan and elastin components of the cartilage, bone and tendons within the joints, should be amenable to treatment with inhibitors of the collagenases, proteoglycanases (stromelysins) and gelatinases currently thought to be the major enzymes involved.
These enzymes have been detected in extracts of synovial and cartilage tissue, and have also been extensively studied in tissue cultures of a wide range of connective tissues. Apart from control of the biosynthesis, secretion and activation of the enzymes, the most important natural regulation of these enzymes in normal and diseased states, is considered to be the endogenous production of inhibitors such as the family of Tissue Inhibitor of Metalloproteases (TIMPS), and alpha-2 macroglobulin. An imbalance between the local levels of the proteolytic enzymes and natural inhibitors will allow destruction of connective tissue components to occur.
The compounds described in the present invention, being synthetic and low molecular weight inhibitors of this family of enzymes, offer a therapeutically useful way in which a more normal or non-pathological balance between inhibition and enzymic activity can be restored: they thus act to complement and supplement the endogenous enzyme inhibitors. Indeed, because these enzymes usually act only within restricted pericellular environments, before being inactivated by inhibitors circulating in the blood and present in most inflammatory exudates, the low molecular weight inhibitors disclosed here may be more WO 91/15506 PCT/GB91/00529 4 effective than endogenous proteinaceous inhibitors that are excluded by their size from the localized regions of connective tissue destruction.
European Patent Application 88310492.9 (Beecham Group) discloses.a class of phosphorus derivatives having activity as inhibitors of collagenase and utility in the treatment of rheumatoid arthritis and related diseases in which collagenolytic activity is a contributing factor.
Novel structurally related compounds have now been discovered, which are collagenase inhibitors and thus of 'potential utility in the treatment of diseases in which collagenolytic activity and tissue remodelling is implicated.
According to the present invention there is provided a compound of general formula or a salt, solvate or hydrate thereof:
R
1 R OH 0 OR H H
R
3
(I)
in which, R is hydrogen, C1-6 alkyl or optionally substituted benzyl; R, is hydrogen or C.i_ alkyl; WO 91/15506 PCT/GB91/00529 5 R2 is C3- 6 alxyl; and R3 and R4 are joined together as -(CH2)p-X-(CH2)q- where p is an integer from 1 to 9, q is an integer from 2 to and the moiety -(CH 2 p is adjacent to the carbon atom bearing R 3 marked with an asterisk in formula and X is -NR 5 where R5 is selected from hydrogen, C 1 -6alkyl,
C
2 -6alkanoyl, C 1 -6alkoxycarbonyl, aroyl, aralkyl or aralkyloxycarbonyl in each of which the aryl moiety is optionally substituted.
Unless otherwise specified, each alkyl group is preferably a C 1 -8 group, more preferably C 1 and may be a straight chain or branched. An aryl moiety is preferably phenyl.
Optional substituents for an aryl moiety may be selected from OH, C 1 -6 alkyl, C1-6 alkoxy and halogen.
R is preferably hydrogen, methyl, ethyl or benzyl, especially hydrogen.
Values for R1 include hydrogen, methyl, ethyl, isopropyl and n-butyl. As an alkyl group, R 1 is pre'Lrably methyl or ethyl.
R
2 is preferably a C 4 alkyl group, such as n-butyl, iso-butyl or sec-butyl, especially iso-butyl.
Values for R 3 and R 4 together include -(CH2)p-X-(CH2) c where p and q have values such that R3 and R 4 form part of an 11- or 13 to 16-membered azalactam structure, and X is
-NR
5 where R 5 is hydrogen, methyl, benzyl, t-butoxycarbonyl or benzyloxycarbonyl.
WO 91/15506 PCT/GB91/00529 6 Most preferred are compounds where R 3 and R4 are joined together as -(CH 2 )p-X-(CH 2 where p is 4 and q is 5 or p is 3 and q is 6 or p is 4 and q is 6 or p is 4 and q is 3 and X is -NR 5 where R5 is hydrogen or methyl.
The compounds of formula may form salts with bases e.g. sodium hydroxide. The compounds of formula have a basic nitrogen atom and may form acid addition salts e.g. with hydrochloric acid. Such compounds form part of the present invention.
Where compounds of formula or salts thereof, form solvates or hydrates, these also form an aspect of the invention.
The compounds of formula have at least two, and may have three or more asymmetric centres and therefore exist in more than one stereoisomeric form. The invention extends to all such forms and to mixtures thereof, including racemates, and diastereoisomeric mixtures.
Preferred isomers are those having the S-configuration at the chiral centre bearing R 2 and the S-configuration at the chiral centre bearing R 3 marked with an asterisk in formula The compounds of formula or their salts, solvates or hydrates are preferably in pharmaceutically acceptable form. By pharmaceutically acceptable form is meant, inter alia, of a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.
WO 91/15506 PCT/GB91/00529 7 The compounds of formula or their salts, solvates or hydrates are preferably in substantially pure form.
A substantially pure form will generally contain at least by weight, preferably 75%, more preferably 90% and still more preferably 95% or 99% or more of the compound of formula I or its salt or solvate.
Compounds of formula or their salts, solvates or hydrates may be isolated as crystalline solids or in the form of foams or gums.
A preferred pharmaceutically acceptable form is the crystalline form.
The present invention provides the compounds of formula or pharmaceutically acceptable salts, solvates or hydrates thereof for use as active therapeutic agents, particularly as agents for treatment of conditions in which degradation of connective tissue and other proteinaceous components of the body occurs, such as musculo-skeletal disorders resulting from collagenolytic activity, particularly rheumatism and/or arthritic conditions, and tissue remodelling.
Compounds of formula also have potential utility in the treatment of cancer; for preventing myelin degradation in the central and peripheral nervous system; and in other conditions in which members of the collagenase family of neutral metalloproteases have pathological or other roles.
The present invention also provides a process for the preparation of a compound of formula which comprises converting a group R 20 to hydrogen by cleaving a group R 20 from a compound of formula (II): WO 91/15506 PCT/GB91/00529 8-
R
1
R
O 202 N R4
OR
2 1
H
R
3
(II)
wherein R 2 0 is alkyl, optionally substituted phenyl, or optionally substituted benzyl and R 21 is hydrogen, alkyl, optionally substituted phenyl, or optionally substituted benzyl and R 1
R
2
R
3 and R 4 are as defined in formula and where necessary, converting R 21 to hydrogen.
Cleavage of R 20 and where necessary R 21 may be carried out in aqueous acid or alkali or using a trimethylsilyl halide, preferably bromotrimethylsilane, in an inert solvent, for example dichloromethane or acetonitrile.
Benzyl esters may alternatively be removed by hydrogenolysis or other standard debenzylation procedures.
Phenyl residues may be removed by hydrogenation over platinum oxide.
When both R20 and R21 are alkyl, cleavage of R 2 0 only, to give to a compound of formula (II) in which R20 is hydrogen and R 21 alkyl, which is a compound of formula (I) in which R is alkyl, may be carried out by treatment with excess alkali under mild conditions, for example with aqueous sodium hydroxide in an alcoholic solvent at room temperature.
Similarly, where R20 is optionally substituted benzyl and R21 is alkyl, the benzyl group only may be cleaved by WO 91/155T06 PC/GB91/00529 9 hydrogenation to give a compound of formula (II) in which
R
20 is hydrogen and R 2 1 is alkyl.
Cleavage of an R 21 alkyl group may thereafter be carried out as described above to give a compound of formula (I) in which R is hydrogen.
When R in a compound of formula is hydrogen and R 21 in a compound of formula (II) is not hydrogen, then cleavage of both R 21 and R20 is conveniently effected in a single reaction. Preferably R 20 and R21 are both alkyl, such as methyl or ethyl, or benzyl.
It will be appreciated that compounds of formula (II) in which R 21 is hydrogen are themselves compounds of the invention of formula Compounds of formula (II) may be prepared by treating a compound of formula (III):
R
1
R
2 OR21 0 P H O
OR
21 (III) in which R 1
R
2
R
20 and R21 are as defined in formula (II) (except that R21 is not with a compound of formula (IV):
O
2
N
HN NHR 4
R
.3
(IV)
WO 91/15506 PCIGB91/00529 10 in which R 3 and R 4 together are as defined in formula The reaction is preferably carried out in the presence of a coupling agent,, such as dicyclohexylcarbodiimide or (dimethylamino) propyl] carbodiimide hydi';hloride in the presence of 1-hydroxybenzotriazole, or using 1,l'-carbonyldiimidazole, in an inert solvent such as dichloromethane or acetonitrile.
Selective cleavage of the group R 21 may then be carried out using the procedures described above for the preparation of compounds of formula to give compounds of formula (II) in which R2 1 is hydrogen.
The intermediate compounds of formula (III) may be prepared by treating a compound of formula or a salt thereof: 0 P NH 2 2
OR
2 1
(V)
in which R 1
R
2 0 and R21 are as defined in formula with a compound of formula (VIA) or (VIB) or a salt thereof:
R
2
R
2 R11 C0 2
R
12 0 C0 2
R
12 (VIA) (VIB) WO 91/15506 PCT/GB91/00529 11 in which R2 is as defined in formula R 11 is a leaving group such as halogen, methanesulphonyloxy or trifluoromethanesulphonyloxy and R12 is hydrogen or a carboxyl protecting group, and thereafter removing an R12 carboxyl protecting group. Preferred method is the reaction of with When a compound of formula (VIB) is used, the reductive amination may be carried out by hydrogenation over a noble metal catalyst such as palladium on carbon or by reaction with sodium cyanoborohydride at pH 6 to 7. Lower alkyl alcohol solvents such as methanol and ethanol are suitable for both reactions. These reactions may be carried out in the presence of molecular sieves.
A hydrogenation reaction is preferred but this process precludes the use of compounds of formulae and (VIB) in which any of R 20
R
21 or R12 'is benzyl. Preferably a carboxyl protecting group is a methyl or ethyl ester.
Ester protecting groups may be removed under standard basic hydrolysis conditions using dilute base such as 1 Normal aqueous sodium hydroxide in methanol or aqueous potassium hydroxide in 1,4-dioxane.
When the compound of formula is in the form of the free base, the compound of formula (VIB) is suitably an a-keto ester (R 12 alkyl).
When the compound of formula is a salt, such as the hycrochloride salt, the compound of formula (VIB) is suitably a salt of an a-keto acid (R 12 for example the sodium salt.
WO 91/15506 PCT/GB9l/00529 12 The preparation of compounds of formula (III) using a compound of formula (VIA) may be carried out under standard alkylation conditions. A halogen leaving group is preferably bromine and an oxygen-based leaving group is preferably trifluoromethanesulphonyloxy.
Compounds of formula (III) may alternatively be prepared by condensing a compound of formula (VII) or a salt thereof: R2
H
2 N C02 1 2
(VII)
in which R2 is as defined in formula and R12 is a carboxyl protecting group with an aldehyde, R 1 -CHO in which R1 is as defined in formula and treating the condensation product with an appropriate dialkyl or trialkyl phosphite, for example dimethyl phosphite, and thereafter removing the carboxyl protecting group. The carboxyl group is conveniently protected as an alkyl or benzyl ester which may be removed using standard hydrolysis or hydrogenation conditions.
As described above in connection with reductive amination of compounds of formula (VIB), where a benzyl protecting group R 12 is removed by hydrogenation then R20 and R21 are restricted to alkyl.
Alternatively, compounds of formula (II) in which R20 and R21 are alkyl or optionally substituted benzyl may be prepared by the reaction of a compound of formula (VIII): WO 91/15506 PCT/GB91/00529 13 R2 o
H
2 N NH R 4
R
3
(VIII)
in which R 2
R
3 and R 4 are as defined in formula with a compound of formula (IX):
R
1
OR
2 0 O^ 11
OR
(IX)
in which R 1 is as defined in formula R20 and R21 are alkyl, optionally substituted phenyl, or optionally substituted benzyl and R 11 is a leaving group as defined for formula (VIA), in the presence of a base such as triethylamine or Proton Sponge (1,8-bis(dimethylamino)-naphthalene), or using anhydrous potassium carbonate in an alcoholic solvent.
Where R11 is an oxygen-based leaving group, for example trifluoromethanesulphonyloxy, which is preferred, displacement of the .eaving group is conveniently carriec out in the presence of Proton Sponge in an inert solvent such as acetonitrile or dichloromethane, over a period of several days in the absence of light.
WO 91/15506 PCT/GB91/00529 14 A further alternative preparation of compounds of formula (III) may be carried out by reacting a compound of formula (IX) as hereinbefore defined with a compound of formula (VII) in which RL2 is a carboxyl protecting group, using conditions as described for the reaction of compounds of formula (VIII) with compounds of -formula and thereafter removing the protecting group R 12 Suitable carboxyl protecting groups include alkyl, benzyl, trialkylsilyl and trialkylsilylethyl groups. A trialkylsilyl protecting group, for example trimethylsilyl, is especially useful in that it may be readily incorporated, in situ, for example by addition of hexamethyldisilazane to the reactants in acetonitrile in the presence of triethylamine, and selectively removed in aqueous methanol, without imposing any limitations on the value of R20 and R21. Other -silylating agents include trimethylsilyl chloride and N,N-diethyltrimethylsilylamine.
An R 12 alkyl carboxyl protecting group may be removed by base hydrolysis, for example using sodium hydroxide in aqueous methanol or potassium hydroxide in aqueous 1,4dioxane.
It will be appreciated that where the carboxyl protecting group R 12 is alkyl, R 20 and R 21 may be alkyl, phenyl or benzyl derivatives, but where R12 is a benzyl group, and P 21 are limited to alkyl and phenyl.
When compounds of formula (III) are prepared by this route, it is preferred that R20 and R21 are benzyl and R,.
is trifluoromethanesulphonyloxy in the compound of formula (IX) and R 12 is trimethylsily) or methyl in the compound of formula (VII).
WOP 91/15506 PCT/GB91/00529 15 Compounds of formula (VIII) may be prepared by treating a compound of formula (VII): R2 1
H
2 N C0 2
R
12
(VII)
in which R2 is as defined in formula R 12 is hydrogen and wherein the amino group is optionally protected, with a compound of formula (IV) as hereinbefore defined, in the presence of a coupling agent as hereinbefore described for the preparation of compounds of formula (II) from compounds of formulae (III) and (IV).
Compounds of formula (IX) may be prepared from hydroxyalkylphosphonate derivatives by conversion of the hydroxyl group to the leaving group R 11 by conventional methods.
For example, where R11 is trifluoromethanesulphonyloxy, trifluoromethanesulphonic anhydride may be added to a solution of the hydroxyalkylphosphonate in an inert solvent such as dichloromethane, the reaction being carried out at reduced temperature under an inert atmosphere, according to the general method of E. Vedejs et al., Journal of Organic Chemistry 50, 2165, (1985).
Hydroxyalkylphosphonate compounds may in turn be prepared by reaction of the corresponding phosphite, for example dibenzylphosphite, with an aldehyde R 1 -CHO in which R, is as defined in formula according to the general method of F. Texier-Boullet and A. Foucaud, Synthesis, 916 (1982). Benzyl and alkyl phosphites are either commercially available compounds or can be prepared from commercially available starting materials by standard methods.
WO 91/15506 PCr/GB9/1/00529 16 Intermediate compounds of formula are either known compounds or may be prepared from known aminoalkyl phosphonic acid derivatives using standard procedures to introduce R20 and R 21 as required.
Protection of the amine function during these reactions may be necessary.
Introduction of an R20 or R 21 methyl group may be effected by reaction with diazomethane in a suitable inert solvent.
Compounds of formula of fixed configuration may be prepared by the general method of R. Jacquier et al., Phosphorus and Sulfur 36, 73, (1988).
Compounds of formula (IV) may be prepared by oxidising the primary alcohol function in a compound of formula
Y
H NH H Z-N- (CH 2 )p N-(CH 2 )q-OH 0
(X)
wherein p and q are as defined in formula Y is a nitrogen protection group, and Z is R5 to give the corresponding aldehyde, followed by removal of Z where Rg is an acyl group; cyclisation and reduction; and thereafter, as necessary, removing the nitrogen protection group Y and interconverting R 5 WO 91/15506 PCT/GB91/00529 17 Suitable nitrogen protection groups include t-butoxycarbonyl (BOC) and benzyloxycarbonyl groups.
The oxidation may be carried out using pyridinium chlorochromate, or under Swern oxidising conditions, for example by treatment with dimethylsulphoxide and an acyl halide followed by triethylamine, as described by D. Swern et al., J. Org. Chem., 43, 2480 (1978). The cyclisation and reductive amination step may be effected by catalytic hydrogenation over a suitable noble metal catalyst, for example palladium on carbon, or by reaction with sodium cyanoborohydride or sodium borohydride. In some cases the yield of azalactams may be increased by carrying out the reductive amination step under acidic conditions.
Nitrogen protection groups may be removed by standard methods. A t-butoxycarbonyl group may be removed by treatment with trifluoroacetic acid at reduced temperature. Where Z is a nitrogen protection group, it may be selected to undergo concomitant cleavage during the cyclisation reaction to give a compound in which R5 is hydrogen. For example, when Z is a benzyloxycarbonyl group, it will be readily removed by catalytic hydrogenation.
An R 5 hydrogen may be interconverted to an R 5 Cl..
6 alkyl, aralkyl or aryl group. The secondary amine group in the azalactam ring may be alkylated to form an R 5 alkyl group.
For example, the amine group may be methylated to form an
R
5 methyl group. The methylation step may be effected by catalytic hydrogenation over a suitable noble metal catalyst, for example palladium on carbon, in the presence of aqueous formaldehyde. Other suitable methylation procedures are described by E. Askitoglu et al., Helv.
WO 91/15506 PCT/GB91/00529 18 Chim. Acta., 68, 750, (1985); E. Engler et al., Helv.
Chim. Acta., 68, 789, (1985); and M. Lennon et al., J.
Chem. Soc. (Perkin 622, (1975).
Compounds of formula may be prepared by reacting a compound of formula (XI):
Y
L
H NH
Z-N-(CH
2 )p OH
(XI)
wherein p, Y and Z are as defined for formula with a compound of formula (XII): H2N-(CH 2 )q-OH (XII) wherein q is as defined for formula The reaction may be carried out using standard procedures for forming an amide from a carboxylic acid and an amine, for example using a coupling agent such as 1,1'carbonyldiimidazole, 1,3-dicyclohexylcarbodiimide or 1-(3dimethylaminopropyl)-3-ethylcarbodiimide.
Compounds of formula (XI) are di-aminoalkanoic acid derivatives. These are known compounds or may be prepared from known starting materials by standard methods.
For example the compound of formula (IV) in which R3 and
R
4 together are -(CH2)p-X-(CH 2 q where p is 3, q is 6 and WO 91/15506 PCT/GB91/00529 19 X is -NH- is prepared frm,. a compound of formula (XI) derived from ornithine which is commercially available.
The compounds of 'formula (IV) in which R 3 and R 4 together are -(CH 2 )p-X-(CH 2 where p is 4, q is 3, 5 or 6 and X is -NH- are prepared from a compound of formula (XI) derived from the amino acid lysine. The compound of formula derived from S-lysine, in which Y is t-butoxycarbonyl and Z is benzyloxycarbonyl, is commercially available.
Similarly, the compound of formula (IV) in which R 3 and R 4 together are -(CH 2 )p-X-(CH 2 where p is 1, q is 8 and X is -NH- may be prepared from 2,3-diaminopropionic acid.
The compounds of formula (VII) are either known amino acid derivatives or can be made from these derivatives by known methods. Compounds of formula (VIA) and (VIB) are either known compounds or may be prepared from known compounds by known methods.
The intermediates of formulae (III), and certain intermediates of formula disclosed herein are novel compounds and form an aspect of the present invention as do the described processes for their preparation.
Where obtainable, pharmaceutically acceptable salts of the compounds of formula may be formed conventionally by reaction with the appropriate acid or base. Solvates may be formed by crystallization from the appropriate solvent.
WO 91/15506 PCT/GB9i/00529 20 As mentioned previously, the compounds of formula (I) exist in more than one diastereoisomeric form. Where the processes of the invention produce mixtures thereof, the individual isomers may be separated one from another by chromatography e.g. HPLC.
Alternatively, separate diastereoisomeric compounds of formula can be obtained by using stereoisomerically pure starting materials or by separating desired isomers of intermediates at any stage in the overall synthetic process, and converting these intermediates to compounds of formula It will be appreciated that where a single diastereoisomer of a compound of formula is prepared by more than one process variant as hereinbefore described, each of which allows a different chiral centre to be defined, it may be possible to deduce the configuration at a chiral centre which is not pre-determined using a particular process variant.
Furthermore, it will be appreciated that although the absolute configuration at a particular chira-l centre may not be known, it is possible to characterise a given diastereoisomer relative to its epimer by reference to the direction in which the plane of polarised light is rotated.
The present invention further provides a pharmaceutical composition, which comprises a compound of formula (I),or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
*;VO 91/15506 PCT/GB91/00529 21 A composition of this invention is useful in the treatment of musculo-skeletal disorders, particularly arthritic diseases and for modulation of tissue remodelling.
A composition of the invention also has potential utility in the treatment of cancer; for preventing myelin degradation in the central and peripheral nervous system; and in other conditions in which members of the collagenase family of neutral metalloproteases have pathological or other roles.
A composition of the invention, which may be prepared by admixture, may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner. These conventional excipients may be employed in conventional manner, for example as in the preparation of compositions of related peptide enzyme inhibitors, such as the ACE inhibitor enalapril.
A composition of the invention may be adapted for oral, topical, rectal or parenteral administration but oral administration is preferred. Parenteral compositions may be administered intravenously, intramuscularly, intraarticularly, intradermally, subcutaneously or into the cerebro-spinal fluid.
Preferably, a pharmaceutical composition of the invention is in unit dosage fortr and in a form adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment or prophylaxis of any of the disorders mentioned above.
WO 91/15506 PC~T/GB91/00529 22 The suitable dosage range for the compounds of the invention may vary from compound to compound and may depend on the condition to be treated. It will also depend, inter alia, upon the relation of potency to absorbability and the mode of administration chosen.
The compound or composition of the invention may be formulated for administration by any route, the preferred route depending upon the disorder for which treatment is required, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage.
Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
The compositions, for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
Solid compositions may be obtained by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions em'nying large quantities of fillers. When the composition is in the WO 91/15506 PCT/GB91/00529 23 form of a tablet, powder, or lozenge, any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated accordinr to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.
For example, in a hard gelatin capsule containing the required amount of a compound of the invention in the form of a powder or granulate in intimate mixture with a lubricant, such as magnesium stearate, a filler, such as microcrystalline cellulose, and a disintegrant, such as sodium starch glycollate.
Compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or nonaqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
WO 01/15506 PCT/GB91/00529 24 The compounds of this invention may also be administered by a non-oral route. In accordance with routine pharmaceutical procedure, the compositions may be formulated, for example for rectal administration as a suppository or for parenteral administration in an injrctable form. For injection, for example by intraarticular injection or by injection into the cerebrospinal fluid or via other routes which will gain access to sites of demyelination, such as by intramuscular, intradermal or subcutaneous injection, as freely soluble solutions or as poorly dispersed depot stores, the compounds of the invention may be presented in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogenfree water or a parenterally acceptable oil or a mixture of liquids, which may contain bacteriostatic agents, antioxidants or. other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives. Such forms will be presented in sterile unit dose form such as ampoules or disposable injection devices or in multi-dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
For topical and percutaneous administration, the preparations may also be presented as an ointment, cream, lotion, gel, spray, aerosol, wash, skin paint or patch.
A unit dose for treating diseases in which enzymes of the collagenase family are involved will generally contain from 10 to 1000 mg and preferably will contain from 10 to 500 mg, in particular 10, 50, 100, 150, 200, 250, 300, 350, 400, 450 or 500 mg. The composition may be WO 91/15506 PCT/GB91/00529 25 administered one or more times a day, for example 2, 3 or 4 times daily, so that the total daily dose for a 70 kg adult will normally be in the range 10 to 3000 mg. Such a dosage corresponds to approximately 0.15 to 50 mg/kg per day. Alternatively, in particular for injection, the unit dose will contain from 2 to 200 mg of a compound of the invention and be administered in mulSi.ples, if desired, to give the desired daily dose.
The present invention additionally provides a method of treating conditions in which degradation of connective tissue and other proteinaceous components of the body occurs, such as rheumatism and/or arthritic conditions in mammals, such as humans, which comprises administering to the mammal in need of such treatment an effective amount of a compound of formula or a pharmaceutically acceptable salt thereof.
The present invention also provides the use of a compound of formula 'or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment of conditions in which degradation of connective tissue and other proteinaceous components of the body occurs such as rheumatism and/or arthritic conditions.
The following Descriptions and Examples illustrate the preparation of compounds of the invention. All temperatures are expressed in °C.
WO 91/15506 WO 9115506PCT'/GB91/00529 -26 Description 1 Dibenzyl (1-hydroxypropyl) phosphonate (DOJ.
0 (PhCH 2
O)
2 P IT OH
C
2
H
The general method of F. Texier-Boullet and A. Foucaud [Synthesis, 1982, 916] was employed. A mixture of dibenzyl phosphite (31.13 ml, 0.14 mole) and propionaldehyde (10.21 ml, 1 equiv.) was stirred at room temperature and basic alumina (70g) added in one portion.
After standing overnight at room temperature chloroform was added and the alumina collected and washed with chloroform. The filtrate was evaporated to dryness and the resulting clear oil chromatographed on silica gel (600g) with gradi-.4cr elution (ether 5% methanol/ether).
The title compound was obtained as a clear oil which solidified on standing (27.82g, A sample was recrystallized from ether/pentane to give a white crystalline solid, m.p. 81-82'C.
Found: C, 64.09; H,6.71. C 17
H
21 0 4
P
1 requirez C, 63.74; H, 6.61%.
5(CDCl 3 1.04(3H,t,J=7Hz), 1.6-1.95(2H,m), 2.21(lH, brs), 3.8(1H, 2 overlapping triplets,J=5 and 4. 97-5.18 (4H, m) 7.34 (10H,s) WO 91/15506 PCT/GB91/00529 27 Description 2 Dibenzyl ((l-trifluoromethanesulphonvloxy)propyl)phosphonate (D2) 0 (PhCHzO) 2 P 0 CF 3
C
2
H
5 0 The title compound was prepared by the general method of E. Vedejs et al. Org. Chem. 1985, 50(12), 2165]. A solution of dibenzyl (l-hydroxypropyl)phos-phonate (Dl) (24.97g, 0.078 mole) in methylene chloride (180 ml) was cooled to -50 0 C under N 2 2,6-Lutidine (11.12 ml, 0.0?5 mole) was added followed by trifluoro- methanesulphonic anhydride (15.1 ml, 0.0898 mole) keeping the temperature -50 0 C. The mixture was allowed to warm slowly to 0°C and then taken into cold ether. The solution was subjected to a rapid aqueous work-up by washing the organic layer with ice-cold water, dilute hydrochloric acid (x2) and finally brine. The organic layer was dried (anhydrous MgSO 4 and evaporated to dryness to give the title compound as a pinkish orange oil (33.77g, 96%) which was used without further purification.
(CDC1 3 1.08(3H,t,J=7Hz), 1.88(2H,m), 4.94(1H,2 overlapping triplets,J=5.5 and 7Hz), 4.88-5.22(4H,m) and 7.35(10H,m).
WO 91/15506 PCT/GB91/00529 28 Description 3 N-(1-(R)-Dibenzyloxyphosphinylpropyl)-(S)-leucine (D3A) and N-(1-(S)-Dibenzyloxyphosphinylpropyl)-(S) -leucine (D3B)
CH
3
CH
3 (PhCH 2
O)
2 P N C0 2
H
H
Method A Following the general method of US 4808741 for the preparation of leucine trimethylsilyl ester a mixture of (S)-leucine 1.15g, 0.0088 mole), hexamethyldisilazane (1.75 ml), and triethylamine (1.38 ml) in acetonitrile (13.5 ml.) was heated at reflux for a total of 4h.
Dibenzyl ((l-trifluoromethanesulphonyloxy)propyl)phosphonate (D2) (4.5g, 0.01 mole) was then added and the mixture maintained at 40-42 0 C for 48h. The reaction can also be carried out at ambient temperature. After cooling the mixture was filtered, washed with methanol and the filtrate evaporated to dryness. The residue was taken up in chloroform and washed with dilute HC1 (x2) and finally water. The chloroform layer was dried (anhydrous Na 2
SO
4 filtered and evaporated to dryness to give an orange gummy solid (3.67g). The crude product was trituratied with the minimum volume of ether/pentane to give a white crystalline solid which after collection, washing with a little cold ether/pentane and drying gave the title compound, R,S isomer (D3A) (0.47g, m.p. 112-115 0
C.
WO 91/15506 WO 9115506PCTrkB91/00529 29 Observed Desorption CI (NH 3 MH 434. C 23
H
32
NO
5 P requires M 433.
EaD0= -23.09' (c=0.97 MeOH) Found: C,63.73; H,7.42; N,3.23. C 3 3 N0 5 P requires C,63.73; H,-7.44; N,3.23%.
S(CDC1 3 0.89 (6H,t) 1.03 (3E,t) 1.25-2.0 2.74 3.28 br 3.73 (1H, br 4.9-5.15 (4H, mn), 7.35 (10H, s).
The other isomer, (S)-dibenzyloxyphosphinyJlpropyl)- (S)-leucine (D3B), can be obtained by preparative HPLC using a Hamilton PRP-1 column, 300 x 7.0mm, 264R with a 40:60 acetonitrile:water eJluent mixture and a flow rate of 4.0 mi/min. Under these conditions the R,S isomer (D3A) elutes first with a retention time of 34.6 min and the S,S isomer (D3B) is well separated at 42.7 min.
For the isomer (D3B): Observed FAB 434. C 23 11 32 N0 5 P requires M 433.
8 (CDC,'l] 3 0.88 (GH,dd), 0.98 1.4 1.52-1.9 (4H,in), 2.72 3.38 4.9-5.15 7.32 (1OH,s).
The S,S isomer (D3B) on coupling with (S)-ainino acid derivatives leads to the S,S,S, series.
Method B A mixture of (S)-leucine methyl ester hydrochloride (0.543g; 0.003 mole), dibenzyl (1-trifluoromethanesulphonyloxy)propyl)phosphonate (D2) (1.35g; 0.003 mole) and anhydrous potassium carbonate (1.0g) in methanol (2 ml) was heated at 50 0 C, with stirring, for 4 hours and then left at room temperature overnight.
WO 91/15506 PCT/GB91/00529 30 The reaction mixture was evaporated to dryness in vacuo, and dissolved in chloroform (5 ml) and filtered. The filtrate, and washings, were combined and chromatographed on silica gel 60 ,(50g) using ethyl acetate-pentane (1:1) as the eluent, to afford a mixture of N-(l-(R)-dibenzyloxyphosphinylpropyl)-(S)-leucine methyl ester and N-(1-(S)-dibenzyloxyphosphinylpropyl)-(S)-leucine methyl ester as an oil (0.55g). The esters can be separated into individual diastereomers by column chromatography on silica gel with initially 50% diethyl ether/pentane as eluent, rising to 100% diethyl ether.
The above mixture of esters (l.lg, 0.0025 mole) in methanol (4.0 ml) was treated with a solution of sodium hydroxide (0.llg; 0.00275 mole) in water (1.5 ml), and the solution was stirred at room temperature overnight. It was evaporated to one third volume, in vacuo,-taken in water and extracted with ether. The aqueous fraction was acidified with citric acid to pH 3-4 and then extracted (5x) with chloroform. The chloroform fraction was dried (Na 2
SO
4 and evaporated to dryness in vacuo to give a mixture of the title compounds (D3A) and (D3B) as an oil that slowly solidified.
Trituration of the product with ether gave N-(l-(R)-dibenzyl-oxyphosphinylpropyl)-(S)-leucine (D3A) (0.34g) as a white crystalline solid, identical to the product obtained by Method A.
Alternatively, the single isomer can be hydrolysed separately. For example N-(1-(S)-dibenzyloxyphosphinylpropyl)-(S)-leucine methyl ester on hydrolysis by the above method gave N-(1-(S)-dibenzyloxyphosphinylpropyl)-(S)-leucine (D3B), m.p. 71-73 0
C.
WO091/15506PC/B9/52 PCr/GB91/00529 31 Descrixption 4 N(X-te rt -But oxvcarbonyl -ben z y oxycarbonyl -lysine- hydroxy) Pentylam' de (D4) H3C
H
H3 N .N CH 2 Ph 100 To a solution of Natr-uoyabnlN-ezl oxycarbonyl-(S)-lysine (7.8g, 21 mmol) in anhydrous dichioromethane (150 ml) maintained at 0 0 C was added 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (4.3g, 22.5 mmol) and 1-hydroxybenzotriazole (3.6g, 26.5 mmole). Tw mix~ture was stirred for 0.5h at 0 0 C, 5-aminopentan--o. (A"K3g, 22.5 mmol) added and stirring continued at room temperature. After 3h the mixture was washed with saturated aqueous NaHCO 3 (60 ml) dried over anhydrous magnesium sulphate and evaporated in vacuo to afford a viscous oil. Purification by flash chromatography [(CHC1 3 :MeOH) (20:1) v/v) gave the titl~a compound (D4) as a clear oil (8.O1g).
Observed 466. C 24
H
39 0 6
N
3 requires M 465.
WO 91/15506 PC'/GB91/00529 32 Description N -tert-Butoxycarbonyl-N-benzyloxycarbonyl- lysine-(4-formyl)butylamide H O H
H
3 C ON O C CH 3 0 N OCH 2 Ph 0 To a stirred solution of oxalyl chloride (1.47g, 12 mmol) in anhydrous dichloromethane (40 ml) maintained under an atmosphere of nitrogen at -60 0 C was added dimethylsulphoxide (1.21g, 15 mmol) dropwise, such that the temperature remained below -50aC. The mixture was left stirring at -60 0 C for 15 minutes, alcohol (D4) (3.6g, 7.7 mmol) diluted in anhydrous dichloromethane (10 ml) was added, and allowed to warm up to -25 0 C over lh. The mixture was then cooled down to -60 0 C, triethylamine (4.7g, 46 mmol) added slowly such that the internal temperature remained below -50 0 C. On completion of addition, the mixture was gradually warmed up to room temperature, washed with water (30 ml) and sat., aq. NaC1 (30 ml). The aqueous washes were back extracted with dichloromethane (2x30 ml) and the combined organic fractions were dried over anhydrous magnesium sulphate and evaporated in vacuo to yield a viscous clear oil.
Purification by flash chromatography [(EtOAc:MeOH) (20:l)v/v] afforded the title compound as an oil (2.8g).
Observed (M+H) 464. C 24
H
37 0 6
N
3 requires M 463.
WO 91/15506 PCFT/GB91/0529 33 Description 6 (S)-3-(N-tert-Butoxycarbonyl)amino-8-(N-benzyloxycarbonyl)-1,8-diazacvclotridecan-2-one (D6) H O H3c°
H
0 OCHzPh Method A The aldeL, e (D5) (1.8g, 3.88 mmol) was dissolved in ethanol (180 ml) and hydrogenated over 5% palladium on charcoal (200 mg) at atmospheric pressure and 35 0 C for 72h. The suspension was filtered through Kieselguhr and evaporated in vacuo to give crude 3-[N-tert-butoxycarbonyl]amino-(S)-1,8-diazacyclotridecan-2-one. The crude amine was dissolved in a mixed solvent system of tetrahydrofuran/water, (6:20 ml) v/v cooled to o0C and treated with benzylchloroformate (0.66g, 3.88 mmol) and excess sodium carbonate to maintain a pH between 10 and 11. The mixture was left stirring at room temperature overnight, washed with ethyl acetate (3x25 ml), and the combined organic fractions dried over anhydrous magnesium sulphate and evaporated in vacuo to afford a clear oil.
Purification by flash chromatography [(EtOAc:MeOH) (20:1)v/v] yielded the title compound (D6) as a white solid (0.2g).
Observed M 447. C 24
H
37 0 5
N
3 requires M 447.
WO 91/15506 P~/GB91/00529 34 Method B The aldehyde (D5) was hydrogenated at about 100 psi over palladium on charcoal in methanol, and then in acidic methanol to afford crude (S)-3-[N-tertbutoxycarbonyl)amino-1,8-diazacyclotridecan-2-one.
The amine was treated with benzylchloroformate and purified as descried in Method A to yield the identical title compound (D6).
Description 7 (S)-3-Amino-8-[N-benzyloxycarbonvl -1,8-diazacyclotridecan-2-one, trifluoroacetate salt (D7) H 0 TFA. H N O OCH2Ph A cooled solution of the lactam (D6) (0.19g, 0.42 mmol) in dichloromethane (5 ml) was treated with trifluoroacetic acid (2 ml). After 0,5h the solvent was evaporated under reduced pressure, the residue diluted with dichloromethane (15 ml) and washed with sat. aq. NaCl ml). The organic fraction was dried over anhydrous magnesium sulphate and evaporated in vacuo to give crude title compound (D7) as an oil. This was used as such without further purification.
WO 91/15506 PCT/GB91/00529 35 Description 8 N- N-(R)-(1-Phosphonopropyl)-(S)-leucyll amino- 8-(N-benzvloxvcarbonyl)-1,8-diazacvclotridecan-2-one, dibenzvl ester (D8)
CH
3
C
2
H
5
H
N
o H O OCH2Ph A solution of N-(1-(R)-dibenzyloxyphosphinylpropyl)- (S)-leucine (D3A) (0.194g, 0.45 mmol) in anhydrous dichloromethane (20 ml) maintained at O0C was treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.085g, 0.45 mmol) and 1-hydroxybenzotriazole (0.079g, 0.58 mmol). After stirring for the reaction mixture was sequentially treated with lactam (D7) (0.15g) and N,N-diisopropyl-ethylamine (0.12g, 0.89 mmol). Stirring was continued for 18h at room temperature, then the mixture was washed with sat. aq.
NaHCO 3 (2x20 ml), and sat. aq. NaC1 (2x20 ml). The aqueous washes were back-extracted with dichloromethane and the combined organic fractions dried over anhydrous magnesium sulphate, and evaporated in vacuo to yield an oil. On purification by flash chromatography methanol in chloroform), the title compound (D8) was obtained as a clear oil (0.110g).
Observed (M+H) 763. C 42
H
59
N
4 0 7 P requires M 762.
WO 91/15506 WO 9115506PCr/GB91 100529 36 8 l.2(3H,t), 1.25-l.93(18H,m), 2.70(lHi,m), 2.90(lH,rn), 3.18(2H,m), 3.39(2H,dt), 3.62(2H,M), 4.23(lH,m), 4.92-5.12(6H,m), 6.0(2.H,brs), 7.28-7.42 Description 9 Natr-uoyabnl-6bnvoyabnl -ornithine- (6-hydroxy) hexv lamide (D9)
H
3 C~ TH 0~
Z~X
CH3 0 H OQH 2 Ph
H
A solution of Natr-uoyabnl-cbnyoyabnl (S)-ornithine (12g, 0.033 mci) in anhydrous dichioromethane (200 ml) maintained at 0 0 C, was treated sequentially with 1- (3-dimethylaminopropyl) -3ethylcarbodiimide hydrochloride (7.5g, 0.039 mol), and 2.hydroxybenzotriazole (5.3g, 0.039 mol). The solution was stirred at 0 0 C for 1 h, treated with 6-aminohexan-l-ol (4.6 g, 0.039 mol) and left stirring overnight at room temperature. The mixture was then washed with saturated aqueous NaHCO 3 dried over anhydrous magnesium sulphate, and evaporated in vacuo to afford a viscous oil.
Purification by flash chromatography [(CHCl 3 :MeQH) gave the title compound (D9) as a clear oil (9.1g).
observed 466. C 24
H
39 0 6
N
3 requires M 465.
WO 91/15506 PTG9/02 PCr/GB91/00529 37 8(CDCl 3 1.25-l.4(5H,m), l.42-l.62(71H,m), l.78(1H,m), 3.l-3.35(4H,m), 3.6 4.12(111,m), 5.08 (2H, br 5.31(lH,t), 5.42(1H,d), 6.73(lH,brs), 7.3.(5H,m).
Description Natr-uo~eroy-cbnyovabnl -ornithine- )pentyvlamide
H
3
C
0
H
0H
H
The alcohol (D9) (6.5g, 13.9 immol) dissolved in dichioromethane (50 ml) was added to a vigorously stirred mixture of pyridinium chlorochromate (9g, 41.8 mmol) and 4A molecular sieves (20g) in dichloromethane (200 ml).
Additional portions of pyridinium chlorochromate (4g) were added after 30 minutes and,45 minutes. After 1h total reaction time, the mixture was poured into ether (200 ml) and the reaction flask rinsed with ether (3x100 ml) The combined organic fractions were filtered through kieselguhr, and concentrated in vacuo to afford a yellow oil. Purification by flash chromatography E(EtOAc:MeOH) (49;1)v/v then (20:1)v/v] yielded the title compound (D1O) as a viscous oil Observed 464. C 24
H
37
N
3 0 6 requires M 463.
WO 91/15506 PCT/GB91/00529 38 Description 11 (S)-3-(N-tert-Butoxycarbonyl)amino-7-(Nbenzyloxycarbonyl)-1,7-diazacyclotridecan-2-one (D11) H O
H
3 C O N N H3C C 0
N
O OCHPh The aldehyde (D10) (2.5g) in methanol (300 ml) was treated with 5% palladium on charcoal The suspension was hydrogenated at 100 psi and ambient temperature for 48h, treated with 2.5M aqueous hydrochloric acid (2 mi) and hydrogenation continued at the said pressure for a further 24h. The suspension was filtered through kieselguhr and evaporated in vacuo to give crude 3-(N-tert-butoxycarbonyl)amino-(S)-1,7-diazacyclotridecan-2-one. The crude amine was dissolved in a mixed solvent system of tetrahydrofuran/water, (10:40 ml) v/v cooled to 0°C and treated with benzylchloroformate (0.92g) and excess sodium carbonate to maintain a pH between 10 and 11. The mixture was left stirring at room temperature for 4h, solvent partly evaporated in vacuo and the residue extracted with dichloromethane (3x50 ml). The combined organic fractions were dried over anhydrous magnesium sulphate and evaporated in vacuo t& afford a clear oil. Purification by flash chromatography [(EtOAc:MeOH) (50:1) v/v] yielded the title compound (D11) as a white solid (0.2'7g).
Observed M 447. C 2 4
H
3 7 0 5
N
3 requires M 447.
WO 91/15506 WO 9115596PCT/GB91/00529 39 Description 12 -3--Axino-'7- Nbnvoyarovl17 diazacyclotridecan-2-one, trifluoroacetate salt (D12) HO0
TFA.
0 OCH 2 Ph A cooled (O 0 C) solution of the lactam (Dll) (0.13g) in dichloromethane (5 ml) was treated with trifluoroacetic acid (3 ml) After lh the solvent was evaporated under reduced pressure, to afford crude title compound (D12) as an oil,, This was used as such without further purification.
Description 13 -3-tN- (-Phosphonopropyl) S) -leucyll Iamino-7- (N-benzyioxvcarbonyl) 7-diazacyclotridecan-2-one, dibenzyl ester (D13)
CH
3
CH
3 CA H 0 (PhC.1H 2
O)
2 P NH 0 'OMH 2 Ph A solution of N-(1-(R)-dibenzylokcyphosphinylpropyl)- leucine (D3A) (0.115g) in anhydrous dichloromethane ml) maintained at 0 0 C was treated with 1- (3- WO 91/15506 WO 9115596PCI'/GB91/00529 40 dirnethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.056g) and 1-hydroxybenzotriazole (0.036g) After stirring for 0.5h the reaction mixture was sequentially treated with the 'crude lactam (D12), N,N-diisopropylethylamine (0..075g) and stirring continued at room temperature for 4h. 'The mixture was washed with water ml) and sat. aq. NaHCO 3 (2x20 ml). The aqueous washes were back-extracted with dichloromethane and the combined organic fractions dried over anhydrous magnesium sulphate and evaporated in vacuo to yield an oil. On purification by flash chromatography methanol in chloroform), the title compound (D13) was obtained as a white foam (0.125g).
Observed 763. C 42
H
59
N
4 0 7 P requires M 762.
Description 14 Natr-uovabnl-ebnvovabnl -lysine- (6hYdroxy)hexYlamide_(Dl4)
H
3
C
0
H
H
3 C~ 0p H
CH
3 0 N ><rOCH 2 Ph 0 A solution of Na-tert-butoxycarbonyl-NF--benzyloxycarbonyl-- (S)-lysine (15.8g, 0.042 mol) in anhydrous dichioromethane (200 ml) maintained at 0 0 C, was treated sequentially with 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (9.96g, 0.051 mol) and 1-hydroxybenzotriazole (7.0g, 0.051 mol) The solution was stirred WO 91/15506 WO91/5506PCT/GB9I /00529 41 at 000 for 1h, treated with 6-aminohexan-l-o. (4.7g, 0.046 mol), and left stirring overnight at room temperature.
The mixture was then washed with saturated aqueous NaHCO 3 dried over anhydrous magnesium szalphate, and evaporated in vacuo to afford a viscous oil. Purification by flash chromatography ICHCl 3 :MeOH) (20:1) v/v gave the title compound (D14) as a clear oil (16'g).
Observed 480. C 25
H
41
N
3 0 6 requires M 479.
Descrintion Nater ;u xcroy1-6bnz oyabn -lysine- formyl)pentylamide
H
3 C H 01 CH3,.- N OCH 2 Ph 0 A stirred solution of dimethyl sulphoxide (3.63g, 0.046 mol) in anhydrous dichloromethane (2.00 ml) maintained at 0 C, was treated with oxalylchloride (2.58g, 0.0198 mol) diluted in dichloromethane (10 ml) at such a rate, so as to ensure temperature remained below -500C. After stirring for 20 minutes, the alcohol (D14) (6.35g, 0.013 mol) dissolved in dichloromethane (50 ml) was added dropwise over 5 mins. The mixture was stirred at -6500C for 15 mins, warmed up to -35 0 C, stirred -41or a further mins then cooled down to -600C. The solution was treated with triethylamine (8g, 0.08 mol), warmed up to room WO 91/15506 PCT/GB91/00529 42 temperature, washed with water (2x100 ml), dried over anhydrous magnesium sulphate and solvent evaporated under reduced pressure to afford a viscous oil. Purification by flash chromatography [(EtOAc:MeOH) (30:1) v/v] gave the title compound (D15) as an oil Observed (M+H) 478. C 25
H
39
N
3 0 6 requires M 477.
Description 16 (S)-3-(N-tert-Butoxycarbonyl)amino-7-(Nbenzyloxvcarbonvy)-1,8-diazacyclotetradecan-2-one (D16) T O
H
3 CXO "WN <KN
H
3 C C"0 3H O OCH 2 Ph The aldehyde (D15) (5.0g) in methanol (450 ml) was treated with 5% palladium on charcoal The suspension was hydrogenated at 140 psi and ambient temperature for 48h, treated with 2.5M aqueous hydrochloric acid (3 ml) and hydrogenation continued at the said pressure for a further 24h. The suspension was filtered through Kieselguhr and evaporated in vacuo to give crude (S)-3-(N-tert-butoxycarbonyl)amino-1,8-diazacyclotetradecan-2-one. The crude amine was dissolved in a mixed solvent system of tetrahydrofuran/water, (10:40 ml) v/v cooled to 0°C and treated with benzylchloroformate (2.85g) and excess sodium carbonate to maintain a pH between 10 and 11. The mixture was left stirring at room temperature for 4h, solvent WO 91/15506 W091/5506PCT/GB9I /00529 43 partially evaporated in vacuo and the residue extracted with dichloromethane (3xlOO ml). The organic fraction was dried over anhydrous magnesium sulphate and evaporated in vacuo to afford a clear oil. Purification by flash chromatography [(EtOAc:MeOH) (50:1) v/vI yielded the title compound.(D16) as a white solid (2.0g) m.p. 131.5-134.0'C.
Observed M+r 461. C 25
H
39
N
3 0 5 requires M 461.
Description 17 -3-Amino-B- rN-benzvloxvcarbonvl3-1, 8diazacyclotetredd.can-2-one, trifluoroacetate salt (D17) H1 C TMA. i4 I'L 'N
H
N
0 OCH 2 Ph A cooled (0 0 C) solution of the lactam (D16) (0.175g) in dichioromethane (5mi) was treated with trifluoroacetic acid (3 ml) After lh the solvent was evaporated under reduced pressure, to afford crude title compound (D17) as an oil. This was used as such without further purification.
WO 91/15506 PCT/GB91/00529 44 Description 18 (1-Phosphonopropyl) -leucylli amino-8- (N-benzvloxycarbonyl)-1, 8-diazacvclotetradecan-2-one, dibenzyl ester (D18) 0M3
C
2
H
5
H
(PhCH 2 O)P N 1 HN H
N
O OCH 2 Ph A solution of N-(l-(R)-dibenzyloxyphosphinylpropyl)-(S)leucine (D3A) (0.133g) in anhydrous dichloromethane (10 ml) maintained at 0 C was treated with 1-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.065g) and l-hydroxybenzotriazole (0.046g). After stirring for 0.5h the reaction mixture was sequentially treated with the crude lactam (D17) and N,Ndiisopropylethylamine (0.1g) and stirring continued at room temperature for 4h. The mixture was washed with water (10 ml) and sat.aq. NaHCO 3 (2x10 ml). The aqueous washes were back-extracted with dichloromethane and the combined organic fractions dried over anhydrous magnesium sulphate and evaporated in vacuo to yield an oil. On purification by flash chromatography methanol in chloroform), the title compound (D18) was obtained as a white foam (170 mg).
Observed (M+H) 777. C 43
H
61
N
4 0 7 P requires M 776.
WO 91/15506 PCT/GB91/00529 45 Description 19 (S)-3-(N-tert-Butoxycarbonyl)amino-8-(N-methyl)-1,8diazacyclotridecan-2-one (D19) H O
H
3 C 0
H
CH3 N 1o CC) A solution of diazalactam (D6) (0.35g) in methanol (20 ml) was treated with 5% palladium on charcoal (0.2g) and hydrogenated for 24h at atmospheric pressure and room temperature. The suspension was filtered through kieselguhr, and the filtrate diluted with methanol to a -total volume of 50 ml. The solution was treated with palladium on charcoal (0.3g) followed by 40% aqueous formaldehyde (1 ml), and the resulting suspension hydrogenated for 48h at a pressure of 100 psi. The suspension was filtered through Kieselguhr, solvent evaporated in vacuo, to yield an oil which on exposure to diethyl ether solidified. Purification by flash chromatography [(CHCl 3 :MeOH:NH 3 (90:9:0.5) v/v] afforded the title compound (D19) as a pale yellow solid (0.14g).
m.p. 135-137 0
C.
Observed M 327. C 17
H
33
N
3 0 3 requires M 327.
WO 91/15506 PCT/GB91/00529 46 Description (S)-3-Amino-8-fN-methyll-1,8-diazacyclotridecan-2-one, trifluoroacetate salt
H
0
TFA.H
H N N
CH
3 A cooled solution of the diazalactam (D19) (0.175g) in dichioromethane (5 ml) was treated dropwise with trifluoroacetic acid (3 ml). After lh the solvent was evaporated under reduced pressure to afford crude title compound (D20) as an oil. This was used as such without further purification.
Description 21 rN- (I-Phosphonopropyl) -leucyl 11amino- (N-methyl)-1,8-diazacyclotridecan-2-one, dibenzyl ester (D21) a-i 3 C Hc H, H O (PhCH2.0)2 N f" mH(h~l0
N
0 C VH3 A solution of the N-(l-(R)-dibenzyloxyphosphinylpropyl)- (S)-leucine (D3A) (0.133g) in anhydrous dichloromethane ml) maintained at OOC was treated with 1-(3- WO 91/15506 WO 9115506PCT/GR01i/00529 4~7 dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.065g) and 1-hydroxybenzotriazole (0.046g). The mixture was allowed to stir for 0.5h at room temperature, then treated with amine (D20) dissolved in dichioromethane (210 ml), followed by N,N-diisopropylethylamine (0.1g).
After stirring for 18h, the mixture was washed with sat.
aqueous NaCl (2x10 ml), dried over anhydrous magnesium sulphate and solvent evaporated in vacuc to afford an oil.
Purification by flash chromatography methanol in chloroform) gave the title compound (D21) as a white foam (0.17g).
Observed 643. C 35
H
55
N
4 0 5 P requires M 642.
Descition 22 Natr-uov bnlN-bnvovabnl -lysine- (3hydroxy),propylamide (D22) H~ 0
H
3 C CH N ORP 0 A stirred solution of Na-tert-butoxycarbonyl-NEbenzyloxycarbonyl- -lysine (17.2g) maintained at 0 0 C in anhydrous dichloromethane (250 ml) was treated with l-(3dimethylaminopropyl) -3-ethylcarbodiimide hydroch.Loride (7.5g) and l-hydroxybenzotriazole The soluition was stirred at 0 0 C for lh, treated with 3-aminopropan-1-ol (4.08g) dissolved in dichloromethane (50 ml) and left WO 91/15506 W091/5506PCT/GB91 /00529 48 stirring for 18h at room temperature. The solution was then washed with sat. aqueous NaHCO 3 dried over anhydrous magnesium sulphate, and evaporated in vacuo to afford. a viscous oil. Purification by flash chromatography E(EtOAc:MeOH) (49:1) v/vJ gave the title compound (D22) as a clear oil (15..2g).
Observed 438. C 22
H
35
N
3 0 6 requires t4 437.
Description 23 Natr-uovabnlN-'bnyovabnl -lysine- (2formvl) ethylamide (D23)
H
3 C 0 H H EC'H N -,(OCH 2 Ph 0 The t.itle compound (D23) was prepared following the pro'cedure as described for the synthesis of N(X-ter-tbutoxycarbonyl-NE-benzyloxycarbonyl- -lysi4ne- (4formyl)butylamide (DS) (yield: 59%).
Observed 436. C 22
H
33
N
3 0 6 requires M 435.
WO 91/15506 PCr/GB91/00529 49 Description 24 (N-tert-Butoxvcarbonvl) amino-8- (Nbenzvloxvcarbonvl) 8-diazaccloundecan-2-one (D24)- C HH3 0 H 0 0
N
CH3 CJJ3 H N C2P 0 The title compound (D24) was prepared following the procedure described for the synthesis of (S)-3-(N-tertbutoxycarbonyl)amino-7-(N-benzyloxy-carbonyl)-1,7diLz acyclotridecan-2-one (D11) (Yield m.p. 172- 174 0
C.
Description -3-Amino-B- rN-benzvloxycarbonvll 8-diazacycloundecan- 2-one, trifluoroacetate salt
HO
TFA H' I N OCH2Ph The title compound (D25) was prepared following the procedure described for the synthesis of (S)-3~-amino-7-[Nbenzyloxycarbonyl-1,7-diazacyclo-tridecan-2-one, trifluoroacetate salt D12), and used without purification.
WO 91/15506 W091/5506PCI/GB9I /00529 Description 26 (-Phosphonopropyl) (S)-leucyll Iamino-8- (N-benzvloxycarbonyl) -diazacycloundecan-2-one, dibenzyl ester (D6
CH
3
C
2 11 5 H 0 (PhCH 2
Q)
2 P NN 00 OGH 2 Ph The title compound (D26) was prepared following the procedure described for the synthesis of (1-phosphonopropyl)-(S)-leucyl) ]amino-7- (Nbenzyloxycarbonyl) 7-diazacyclotridecan-2-one, dibenzyl ester (D13) (Yield: 44%).
Observed FAB (MvI((hC 2 0) 2 pO3+ 473. C 40
H
55
N
4 0 7 P requires M 734.
Description 27 CS) (-Phosphonopropyl) -leucyll Iamino-B- (N-benzvloxycarbonvl) 8-diazacyclotridecan-2-one, dibenzyl ester (D27)
CH
3
CH
3
C
2
H
5 H 0 2 P' NI II0
N-
0 0 CH 2 Ph WO 91/15506 PCT/GB91/00529 51 A solution of N-(1-(S)-dibenzyloxyphosphinylpropyl)-(S)leucine (D3B) (0.27g) in anhydrous dichloromethane (10 ml) maintained at o0C was treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.125g) and 1hydroxybenzotriazole (0.088g). After stirring for the reaction mixture was sequentially treated with the lactam trifluoroacetate salt (D7) (0.75 mmol) and N,Ndiisopropylethylamine (0.16g). Stirring was continued for 18h at room temperature, then the mixture was washed wji:h sat.aq. NaHCO 3 (2x15 ml), and sat. aq. NaC1 (2x15 ml).
The organic fraction was dried over anhydrous magnesium sulphate, and evaporated in vacuo to yield an oil. On purification by flash chromatography methanol in chloroform), the title compound (D27) was obtained as a clear oil (0.31g).
Observed (M+H) 763. C 42
H
59 0 7
N
4 P requires M 762.
Description 28 -(1-Phosphonopropyl) -(S)-leucyl] amino-8- (N-benzyloxycarbonyl)-1,8-diazacvclotetradecan-2-one, dibenzyl ester (D28)
CH
3
CH
3 2 5 .C2H H 0 A N
N
2 P N 0 H 0 H 0 OCH 2 Ph A solution of N-(1-(S)-dibenzyloxyphosphinylpropyl)-(S)leucine (D3B) (0.091g) in anhydrous dichloromethane ml) maintained at 0 C was treated with 1-(3- WO 91/15506 WO 9115506PCT/GB91/00529 52 dimethylarninopropyl) -3-ethylcarbodiimide hydrochloride (0.04g) and 1-hydroxybenzotriazole (0.028g) After stirring for 0.5h the reaction mixture was, -equentially treated !-ith lact~am trifluoroacetate salt (D17) (0.23 minol) and N,N-diisopropylethylamine (0.054g) Stirring was continued for 18h at room temperature, then the mixture was washed with sat. aq. NaCi (2x10 ml). The organic fraction was dried over anhydrous magnesium siilphate, and evaporated in vac-up to yield an oil.
Purification by flash chromatography methanol in chloroformn) afforded the title compound as an oil (0.105g).
Observed 777. C 43
E{
61
N
4 0 7 P requires M 776.
Description 29 .S--N-[N-R)-(l-Phosphonoethyl) -leucvlllIamino-8- (Nbenzvloxvcarbon\'l)-l.8-diazacvclotridecan 2-one, dibenzyl ester (D29A) and ,-3-[N-.rN-(S)-(-phosphonoethlS) leucvll Iamino-8- (N-benzvloxycarbonyl) -1,8diazacyclotridecan-2-one, dibenz vi ester (D29BI_
CH
3
CH
3
CH
3 H 0 (PhCH 2
O)
2 P N 4 1* N 0 10 H 0
OC
2 Ph A solution of the isomeric mixture of acids (D29A) and (D29B) (0.28g) in anhydrous dichloromethane (20 ml) maintained at 0 0 C was treated with 1- (3dimethylaminopropyl) -3-ethylcarbodiimidle hydrochloride (0.137g) and 1-hydroxybenzotriazole (0.097g) After WO 91/15506 W091/5506PCT/GB91/00S29 53 stirring for 0.5h the reaction mixture was sequentially treated with lactam (D7) (0.072 mmol) and N,Ndiisopropylethylamine (0.185g) Stirring was continued for 18h at room t 'emperature, then the mixture was washed with sat. ag. NaCl (20 ml). The organic fra:tion was dried over anhydrous magnesium sulphate, and evaporated in vacuc to 'ield an oil, On purification by flash chromatography methanol in chloroform), the title compound (D29) was obtained as) oil (0.32g).
Observed FAB 749. C 4 1
H
5 7
N
4 0 7 P requires M 748.
Description (R)-Dibenzyloxvphosphinvlethvl)-(S)-leucine (D30A) and N-C (S)-i.-dibeit-yloxvphosphinylethyl)-(S)-leucine
CH-
3
CH
3
CH
3 2
O)
2 P N -,C0 2
H
01f1 The title mixture of diastereoisomers (D30) was prepared analogously to the method in Description 3, Method B, as a white solid.I Observed FAB 420. C 22
H
30 N0 5 P requires M 419.
WO 91/15506 WO 91/15506PC'I/GB9I /00529 54 Example 1 rN- rN- -1-PhospRhonopropyl) -leucyl I I amino- 1. 8-diazacycordea- n (El) O HO0 NC N 0 H
H
H
A solution of phosphonic diester (D8) (0.11g) in ethanol ml) was hydrogenated over 10% palladium on charcoal at atmospheric pressure for 24h. The solution was filtered through Kieselguhr and solvent evaporated in vacua. The residue was triturated with diethyl. ether (5 ml) to give the title compound as a white solid, 0.057g,. m.p.
178.5-180..5 0
C.
Observed FAB 449. C 20
H
41 0 5
N
4 2 requires M 448.
2.66(lH,rn), 3.05(5H,m), 3.3 (1H,m overlapping with MeOD), 3.58(1E,m), 4.38(lH,m).
WO091/15506 PCr/GB91/00529 Example 2 (S)-3-[N-fN-((R)-l-Phosphonopropvl)-(S)--leucvll ]arino-1,7diazacy clotridecan-2-ne(E2)
CH
3
C
2
H
5
C'
HO N
N
I, I f 0 H 100 A solution of phosphonic diester (D13) (0.09g) in methanol ml) was hydrogenated over 5% palladium on charcoal at atmospheric pressure for 24h. The solution was filtered through kieselguhr and solvent evaporated in vacuo. The residue was triturated with diethyl ether (5 ml) to give the title compound (E2) as a white solid (0.038g).
Observed 449. C 20
H
4 ,0 5
N
4 P requires M 448.
8 (CDCl 3 0.96(EH,d), l.2(3H,t), l.35-l.9(17H,m), 2.49(lH,m), 2.9(1H,m), 2.98(3H,m),3.l2(lH,m), 3.42(lH,m), 4.33(1H,t).
WO 91/15506 W091/5506PCT/GB91/00529 -56- Example 3 N- -1-Phosphonopropyl) -leucylllamino-1,8diazacyclottradecan-2-one C(q3I GHi 3
C
2
H
5 3 HO H5 H 0 HO PK 14 0 i.H
N
A solution of phosphonic diester (D18) (0.09g) in methanol ml) was hydrogenated over 5% palladium on charcoal (0.08g) at atmospheric pressure for 24h. The solution was filtered through kieselguhr and solvent evaporated in vacuo. The residue was triturated with diethyl ether ml) to give the title compound (E3) as a white.solid (0.05g).
Observed FAB 463. C 21
H
43
N
4 0 5 P requires M 462.
3(CD 3 OD): 0.98(6H,t), l.12(3H,t), l.3-2.l(19H,m), 2.7-3.25(EH,m), 3.72(lH,m), 4.45(lH,m), 4.55(lH,m).
WO 91/15506 W091/5506PCr/GB91/00529 57 Examvle 4 -1-Phosphonopropyvl) -leucyll Iamino-8- (N-methyl) -1,8-diazacyclotridecan-2-one (E4).
CH
3
CFI
3
N
CH
3 A solution of phosphonic diester (D21) (0.09g) in methanol ml) was hydrogenated over 5% palladium on charcoal at atmospheric pressure for 24h. The solution was filtered through kieselguhr and the solvent evaporated in vacuo.
The residue was triturated with diethyl ether (5 ml) to give the title compound (E4) as a white solid (0.051g).
Observed 463. C 21
H
43
N
4 0 5 P requires M 462.
(CD
3 0.98(6H,t), l.1(3H,t), 1.4-2.l(17H,m), 2.7(lH,m), 2.88(311,s), 3.05-3.4(6H,m), 3.65(lHi,m), 4.4 (lH,m).
WO 91/15506 WO 9115506PCI/GB9I /90529 -58 Example -l-Phosphonopropyl) -leucyll 1 amino-i. 8diazacycloundecan-2-one, hydrochloride salt c 3
CH
3 HOH 0 0-HH A solution of phosphonic diester (D26) (0.07g) in ethanol ml) was treated with 5% palladium on charcoal (0.06g) .Id hydrogenated for 18h at atmospheric pressure. The suspension was .filtered through kieselguhr, and the solvent evaporated in vacuo to give a pale brown foam.
The foam was dissolved in ethanol, and treated with 1M ethereal HCl to afford the title compound (E5) as a white solid.
1.7-2.1(llH,m), 2.9-3.2(611,m), 3.6(18,m), 4.45(iH,rn), 4.55 (lH,m).
Example 6 diazacyclotridecan-2-one (E6),
CH
3 HO j 54 HO P N' N it H 0 H N 0
H
WO 91/15506 PCT/GB91/00529 59 A solution of phosphonic diester (D27) (0.29g) in methanol ml) was hydrogenated over 5% palladium on charcoal (0.25g) at atmospheric pressure for 24h. The solution was filtered through ,kieselguhr and solvent evaporated in vacuo. The residue was triturated with diethyl ether ml) to give the title compound (E6) as a white solid (0.16g).
Observed FAB (M+H) 449. C 20 H41N 4 0 5 P requires M 448.
8 (CD30D): 1.0(6H,dd), l.l(3H,t), 1.4-2.0(17H,m), 2.45(lH,m), 2.85-3.2(5H,m), 3.38alH,m), 3.58(lH,m), 4.49(lH,t).
Example 7 N-[N-((S)-1-Phosphonopropvl)-(S)-leucvl]]amino-l, 8diazacyclotetradecan-2-one (E7)
CR
3
SC
2
H
5 H 0 11 H H H
H
A solution of phosphonic diester (D28) (0.085g) in methanol (20 ml) was hydrogenated over 5% palladium on charcoal (0.08g) at atmospheric pressure for 24h. The solution was filtered through kieselguhr and solvent evaporated in vacuo. The residue was triturated with diethyl ether (5 ml) to give the title compound (E7) as a white solid (0.045g).
Observed FAB (M+H) 463. C 21
H
43
N
4 0 5 P requires M 462.
WO 91/15506 W091/5506PCT/GB9I/00529 60 2.85-3.25 (EH,m) 3.65 (1H,m) 4.12 (1H,m) 4.49(lE,di).
Example 8 rN- N- -1-Phosphonoethyl) -leucylllIamino-i 8diazacyclotridecan-2-one (E8A) and phosphonoethyl) -leucyll 1amino-li 8-diazacyclotritlecan- 2-one (E8B)
CH
3 HO AH 0 H 0 H" 0 II
H
A solution of-phosphoiic diester (D29) (0.26g) in methanol ml) was hydrogenated Pver 5% palladium on charcoal (0.2g) at atmospheric pressure for 24h. The solution was filtered through Kieselguhr and solvent evaporated in vacuo. The residue was triturated with diethyl ether ml) to give the title compound (EB) as a white solid as a mixture of diastereoisomers.
Observed FAB 435. C 19
H
39
N
4 0 5 P requires M 434.
WO 91/15506 PC T/GB91/00529 61 COLLAGENASE INHIBITOR ASSAY The test is performed essentially as in Cawston and Barrett, Anal. Biochem. 99, 340-345 (1979). Compounds for testing are dissolved in methanol by sonication and added to collagenase (purified from culture supernatants from the human lung fibroblast cell line, WI-38) in buffer. After a 5 min pre-incubation at 37 0 C, the assay tubes are cooled to 4 0 C and 3 H-acetylated rat skin type I collagen is added. The assay tubes are incubated at 37 0
C
overnight. The 3H-collagen forms insoluble fibrils, which are the substrate for the enzyme.
To terminate the assay, the assay tubes are spun at 12000 rpm for 15 minutes. Undigested 3H-collagen is pelleted, while digested 3 H-collagen is found as soluble peptides in the supernatant. A sample of the supernatant is taken for liquid scintillation counting.
The activity of collagenase inhibitors (IC 50 inhibitory concentration) is expressed as that concentration of compound that inhibits a known (standard) concentration of enzyme by The compounds of Examples E1-E7 had IC 50 values inthe range 6 x 10- 8 3 x 10-6.
Claims (14)
1. A compound of the formula or a salt, solvate or hydrate thereof OH Ol PN 4 OR H R 3 (I) in which, R is hydrogen, C 1 -6 alkyl or optionally substituted benzyl; K 1 is hydrogen or Ci-6 alkyl; R2 is C 3 -6 alkyl; and R3 and R 4 are joined together as -(CH 2 )p-X-(CH 2 q where p is an integer from 1 to 9, q is an integer from 2 to and the moiety -(CH 2 is adjacent to the carbon ,tom bearing R 3 marked with an asterisk in formula and X is -NRg- where R 5 is selected from hydrogen, C 1 6 alkyl, C 2 6 alkanoyl, Cl 1 6 alkoxycarbonyl, aroyl, aralkyl or aralkyloxycarbonyl in each of which the aryl moiety is optionally substituted.
2. A compound according to claim 1 in which R is hydrogen, methyl, ethyl or benzyl. WO 91/15506 PCT/GB91/00529 63
3. A compound according to claim 1 or 2 in which R 1 is hydrogen, methyl, ethyl, isopropyl or n-butyl.
4. A compound according to any one of claims 1 to 3 in which R 2 is n-butyl, iso-butyl or sec-butyl. A.compound according to any one of claims 1 to 4 in which R 3 and R 4 are joined together as -(CH2)p-X-(CH2) q where p and q have values such that R 3 and R 4 form part of an 11- or 13 to 16-membered azalactam structure, and X is -NR 5 where R 5 is hydrogen, methyl, benzyl, t- butoxycarbonyl or benzyloxycarbonyl.
6. A compound according to any one of claims 1 to 5 in which R is hydrogen, R 1 is methyl or ethyl, R 2 is iso- butyl, and R3 and R4 are joined together as -(CH 2 )p-X-(CH 2 where p is 4 and q is 5, p is 3 and q is 6 or p is 4 and q is 6, or p is 4 and q is 3 and X is -NR 5 where R 5 is hydrogen or methyl.
7. A compound according to any one of claims 1 to 6, in which the chiral centres marked with an asterisk in formula have the S-configuration when R3 is other than hydrogen.
8. A compound according to claim 1 which is: (S)-3-(N-[N-((R)-1-phosphonopropyl)-(S)-leucyll]amino- 1,8-diazacyclotridecan-2-one; (S)-3-[N-[N-((R)-1-phosphonopropyl)-(S)-leucyl])amino- 1,7-diazacyclotridecan-2-one; (S)-3-(N-[N-((R)-1-phosphonopropyl)-(S)-leucyl]]amino- 1,8-diazacyclotetradecan-2-one; B2957 64 -1-phosphonopropyl) -leucylJ amino- 8- (N-methyl) 8-diazacyclotridecan-2-one; 1-phoisphonop ropyl1) CS) -leucyl] ]amino- 1, 8-diazacyclound *ecan-2-one, hydrochloride salt; -1-phosphonoprop!) -leucyl] I amino- 1, 8-diazacyclotridecan-2-one; -I -pho sphonop ropy 1) -leucyl] I amino- 1, 8-diazacyclotetradecan-2-one; -1-phosphonoethyl) -leucyl] amino- 8-diazacyclotridecan-2-one and -1-phosphonoethyl) -leucylJ amino- 1, 8-diazacyclotridecan-2-one.
9. A process for the preparation of a compound according to claim 1 which process comprises converting a group R 20 to hydro(_en by cleaving a group R 2 0 from a compound of formula (II): *R R OR 1 0 R substituted penyl anor s y~gnakl optionally substituted phenyl or optionally substituted benzyl and Rl, R 2 R 3 and R 4 are as defined in formula and where necessary, converting 9 21 to hydrogen. A compound of the formula (11) as defined in claim 9 subject to the proviso that R1is not hydrogen. WO091/15506PC/B9/02 PCr/GB91/00529 65
11. A compound according to claim 10 which is N- (-phosphonopropyl) -letkeyl3 3amino- 8- (N-benzyjloxycarbonyl) 8-diazacyclotridecan-2-one, dibenzyl ester; (S)-3-[N-[N-(R)-(l-phosphonopropyl)-(S)-leucyl3 )amino-7- (N-benzyloxycarbonyl) 7-diazacyclotridecan-2-one, dibenzyl ester; (-phosphonopropyl)- CS) -leucyl) 3amino-8- (N-benzyloxycarbonyl) 8-diazacyclotetradecan-2-one, dibenzyl ester; CR) C-phosphonopropyl)- CS) -leucyl) 3amino-B- (N-methyl) 8-diazacyclotridecan-2-one, dibenzyl ester; (S)-3-'[N-N-(R)-(-phosphonopropyl)-(S)-leucyl] ]amino-8- (N-benzyloxycarbonyl) 8-diazacycloundecan-2-one, dibenzy. ester; -(1-phosphonopropyl) -leucyl3 3amino-B- (N-benzyloxycarbonyl) 8-diazacyclotridecan-2-one, dibenzyl ester; (-phosphonopropyl) -3eucyli 3amino-B- (N-benzyloxycarbonyl) 8-diazacyclotetradecan-2-one, dibenzyl ester; -(l-phosphonoethyl) -leucyl) 3amino-8- (N- benzyloxycarbonyl)-l, 8-diazacyclotridecan-2-one, diberizyl ester and 2 (S)-3-(N-(N-(S)-(l-phosphonoethyl)-(S)-leucylJ ]amino-8-(N- bgnzyloxycarbonyl) -1,8-diazacyclotridecan-2-one, dibenzyl ester.
12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a pharmaceutically acceptable carrier. -66-
13. A compound according to any one of claims 1 to 8 or a phaimaceutically acceptable salt, solvate or hydrate thereof, for use as an active therapeutic substance.
14. A compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt, solvate or hydrate thereof, for use in the treatment of conditions in which degradation of connective tissue and other proteinaceous components of the body occurs. The use of a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt, solvate or hydrate thereof, in the manufacture of a medicament for the treatment of conditions in which degradation of connective tissue and other proteinaceous components of the body occurs. ^CC4 C/(AH 40 C liG 1
16. Compounds of the formula A or salts, solvates or hydrates thereof or processes for their preparation, substantially as hereinbefore described with reference to the 20 Descriptions or Examples. DATED this 2nd day of February, 1993 Beecham Group p.l.c. By Its Patent Attorneys DAVIES COLLISON CAVE 930202,papcr\dab.765O2spc,66 INTERNATIONAL SEARCH REPORT International Application No PCT/GB 91/00529 1. CLASSIFICATION OF: SUBJECT MATTER (if severdt classification symoola apply, indicate all) According to International Patent Classification (IPC) or to both National Classification and IPC IPCS C 07 K 5/06, A 61 K 37/64 11. FIELDS SEARCHED Minimum Documentation Searched Classification System Classification Symbols IPC 5 C 07 K, A 61 K Documentation Searched other thin Minimum Documentation to the Extent that such Documents are Included In the Filds SearchedI
111. DOCUMENTS CONSIDERED 10 BE RELEVANT Category Citation of Dm.ument, 11 with Indicaion, where appropriate, of the relevant possages It Relevant to Claim No. 13 Y EP, A, 0320118 (BEECHAM GROUP PLC) 1-15 14 June 1989 see page. 3, line 42 page 8, line 41; description 13; example 5; claims 1-16 cited in the application Py EP, A, 0401963 (BEECHAM GROUP PLC) 1-15 12 December 1990 see page 4, line 37 page 11, line descriptions 7,10,11,16; examples 3,4, 6-8; claims 1-11 A Biochemistry.volume 28, no. 12, June 1989, 1-15 American Chemical Society (Washington, DC, US), D. Grobelny et al.: "Binding energetics of phosphorus-containing inhibitors of thermolysin", pages 4948 -4951 see the whole document *Special categories of cited documonts: 10 later document published alter t.he InterioationaI Wling date A" dcumnt drinnp he gnerl stte l te ar whch I no orpriority date and not In connict with 0i'2 tplcation but "Alcocns deto b e o atcl releae citeatwic snt01ted to understand the princ~iple or theory underlying the consderd t bit4),p& iculr rlevnceInvention earlier document but published on or atter the International document of particular relevance,, the claimed Invention fili ng date cannot be considered novel or cannot be considered to document which rnay throw doubts on priority claim~k) or Involve an Invsntiv2 stop which is cited to rtstablish the publication date of another document of particular relevance;' the claimed Invention citation or other sliecial reason (as specifiad) cannot be considered to Involve an Inventive step wilen the I'D" document referring to an or&l disclosure, use, exhibition or document is combinad with one or more other such J~ocu- other means mstits, such combination being obvious to a person skiled document published prior to the International filing date but In the art. later than the priority date claimed O" document member of the same patent family IV. Date of the Actual Compittion of the lnteirnatlonid Search Data of Malling of this International Search Report 28th June 1991, 27 0. q1- International Searching Authority Signature of Authorized Ofcy EUROPEAN PATENT OFFICE ss.MRTNI Form PCTIISA/210 (second sheet) iavjary 19,15) ANNEX TO THE INTERNATIONA ;L SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. GB 9100529 SA 46300 This anntx lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP ile on 19108191 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of inform~ation. Patent document Publication Patent family Publication cited in search report I date Imember(s) Idate EP-A- 0320118 14-06-89 AU-A- JP-A- US-A- 2507088 1160992 4935404 25-05-89 23-06-89 19-06-90 EP-A- 0401963 12-12-90 AU-A- 5315890 18-10-90 UP-A- 3063294 19-03-91 A. ;Z For momt details about this annex -see Official Journal of t2he European Patent Offic, No. 12182
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909008065A GB9008065D0 (en) | 1990-04-10 | 1990-04-10 | Novel compounds |
GB9008065 | 1990-04-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU7650291A AU7650291A (en) | 1991-10-30 |
AU637903B2 true AU637903B2 (en) | 1993-06-10 |
Family
ID=10674178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU76502/91A Ceased AU637903B2 (en) | 1990-04-10 | 1991-04-05 | Phosphonopeptides with collagenase inhibiting activity |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0527761A1 (en) |
JP (1) | JPH05506651A (en) |
AU (1) | AU637903B2 (en) |
CA (1) | CA2080228A1 (en) |
GB (1) | GB9008065D0 (en) |
IE (1) | IE911165A1 (en) |
NZ (1) | NZ237732A (en) |
PT (1) | PT97281A (en) |
WO (1) | WO1991015506A1 (en) |
ZA (1) | ZA912574B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0520573A1 (en) * | 1991-06-27 | 1992-12-30 | Glaxo Inc. | Cyclic imide derivatives |
GB9122859D0 (en) * | 1991-10-28 | 1991-12-11 | Smithkline Beecham Plc | Novel compounds |
US5326760A (en) * | 1992-06-29 | 1994-07-05 | Glaxo, Inc. | Aminobutanoic acid compounds having metalloprotease inhibiting properties |
US5840698A (en) * | 1994-10-27 | 1998-11-24 | Affymax Technologies N.V. | Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use |
US5831004A (en) | 1994-10-27 | 1998-11-03 | Affymax Technologies N.V. | Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use |
US5827840A (en) * | 1996-08-01 | 1998-10-27 | The Research Foundation Of State University Of New York | Promotion of wound healing by chemically-modified tetracyclines |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8726714D0 (en) * | 1987-11-14 | 1987-12-16 | Beecham Group Plc | Compounds |
EP0401963A1 (en) * | 1989-04-13 | 1990-12-12 | Beecham Group p.l.c. | Phosphonopeptides with collagenase inhibiting activity |
-
1990
- 1990-04-10 GB GB909008065A patent/GB9008065D0/en active Pending
-
1991
- 1991-04-05 JP JP91506973A patent/JPH05506651A/en active Pending
- 1991-04-05 AU AU76502/91A patent/AU637903B2/en not_active Ceased
- 1991-04-05 EP EP91907169A patent/EP0527761A1/en not_active Ceased
- 1991-04-05 CA CA002080228A patent/CA2080228A1/en not_active Abandoned
- 1991-04-05 WO PCT/GB1991/000529 patent/WO1991015506A1/en not_active Application Discontinuation
- 1991-04-08 IE IE116591A patent/IE911165A1/en unknown
- 1991-04-08 ZA ZA912574A patent/ZA912574B/en unknown
- 1991-04-08 PT PT97281A patent/PT97281A/en not_active Application Discontinuation
- 1991-04-08 NZ NZ237732A patent/NZ237732A/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB9008065D0 (en) | 1990-06-06 |
PT97281A (en) | 1992-01-31 |
CA2080228A1 (en) | 1991-10-11 |
JPH05506651A (en) | 1993-09-30 |
AU7650291A (en) | 1991-10-30 |
NZ237732A (en) | 1993-08-26 |
ZA912574B (en) | 1992-10-28 |
EP0527761A1 (en) | 1993-02-24 |
WO1991015506A1 (en) | 1991-10-17 |
IE911165A1 (en) | 1991-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0320118B1 (en) | Peptides with collagenase inhibiting activity | |
US4937243A (en) | Thiol carboxylic acid derivatives and their use as colagenase inhibitors | |
US6518260B1 (en) | (α-aminophosphino) peptide derivatives, method for making same and therapeutic applications thereof | |
AU618669B2 (en) | Novel substituted phosphonic acids and esters | |
AU642046B2 (en) | N-(2-alkyl-3-mercaptoglutaryl)-amino-diaza cycloalkanone derivatives and their use as collagenase inhibitors | |
AU634383B2 (en) | Phosphonopeptides with collagenase inhibiting activity | |
AU637903B2 (en) | Phosphonopeptides with collagenase inhibiting activity | |
EP0159396B1 (en) | Carboxyalkyl peptide derivatives | |
US6391866B1 (en) | (α-aminophosphino) peptides derivative and compositions containing same | |
CA1295333C (en) | Acylaminoalkanoyl compounds | |
AU2783492A (en) | Phosphonopeptides with collagenase inhibiting activity | |
CA1253500A (en) | Acylaminoalkanoyl urethanes or thiourethanes | |
US5212163A (en) | Compounds | |
US5639732A (en) | Phosphorous-containing cysteine and serine protease inhibitors | |
IE921100A1 (en) | Novel compounds |